Evidence map›Paper›PMID 41568163›Full record

ArticleCase reports in endocrinology2026

Initiation of Hybrid Closed-Loop Artificial Pancreas System Improves Glycemic Control in a Hospitalized Type 1 Diabetes: A Case Report and Review.

Shaohua Li, Pin Lv, Haosi Lu, Yang Liu, Yang Shen, Cijing Cai, Xifeng Zeng, Hongyun Lu, Yu Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shaohua LiWards of Cadres, Zhuhai Clinical Medical College of Jinan University (Zhuhai People's Hospital, The Affiliated Hospital of Beijing Institute of Technology), Zhuhai, 519000, China.
Pin LvTangtangquan (Aibaowei Biotechnology Co., Ltd.), Shenzhen, 518102, Guangdong, China.
Haosi LuDepartment of Endocrinology and Metabolism, Zhuhai Clinical Medical College of Jinan University (Zhuhai People's Hospital, The Affiliated Hospital of Beijing Institute of Technology), Zhuhai, 519000, China.
Yang LiuDepartment of Endocrinology, Affiliated Hospital Group of Guangdong Medical University Shenzhen Baoan Central Hospital (Baoan Central Hospital of Shenzhen), Shenzhen, 518102, Guangdong, China.
Yang ShenDepartment of Endocrinology, Affiliated Hospital Group of Guangdong Medical University Shenzhen Baoan Central Hospital (Baoan Central Hospital of Shenzhen), Shenzhen, 518102, Guangdong, China.
Cijing CaiDepartment of Endocrinology, Affiliated Hospital Group of Guangdong Medical University Shenzhen Baoan Central Hospital (Baoan Central Hospital of Shenzhen), Shenzhen, 518102, Guangdong, China.
Xifeng ZengTangtangquan (Aibaowei Biotechnology Co., Ltd.), Shenzhen, 518102, Guangdong, China.
Hongyun LuDepartment of Endocrinology and Metabolism, Zhuhai Clinical Medical College of Jinan University (Zhuhai People's Hospital, The Affiliated Hospital of Beijing Institute of Technology), Zhuhai, 519000, China.
Yu ZhaoDepartment of Endocrinology, Affiliated Hospital Group of Guangdong Medical University Shenzhen Baoan Central Hospital (Baoan Central Hospital of Shenzhen), Shenzhen, 518102, Guangdong, China.ORCID https://orcid.org/0009-0000-1973-2867

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: To observe the efficacy and safety of artificial pancreas (Android-hybrid closed-loop [HCL] system) in patients with type 1 diabetes mellitus (T1DM), and to compare it with insulin multi-injection therapy. Case presentation: A patient with long course of type 1 diabetes was treated with multiple injections of insulin, Android-HCL therapy, and sequential multiple injections of insulin. The intraday glucose fluctuation (especially after lunch, before sleep, and during sleep) of the Android-HCL system was significantly superior to that of the sequential multi-injection insulin therapy. The administration of artificial pancreas system (APS) could significantly reduce the occurrence of Grade 2 hypoglycemia events. Conclusion: Artificial pancreases are feasible for inpatients with type 1 diabetes and may be preferable to conventional insulin therapy.

Indexed as

android artificial pancreas systemclosed-loop insulin infusion systemtype 1 diabetes

Identifiers

PMID41568163
PMCPMC12816969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.